Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
about
Oncolytic adenovirus-mediated therapy for prostate cancerThe HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replicationTherapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimeticDouble-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironmentOncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumorsTat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).Islet engraftment and revascularization in clinical and experimental transplantation.
P2860
Q27004796-86D2B1F5-8F73-4180-A2F2-EF510E576F03Q28477188-618B53B2-40ED-467C-8108-1310B90801BFQ30300019-14771EFC-43E8-46DB-8DBF-B1BF8BBE3E9FQ33527419-52C5E983-E743-4C1B-9444-879CEE11B776Q33718737-DC457C09-ECE6-46E1-B936-389A1537EB79Q34178183-2E22E081-E1B7-46F8-8E0A-21490405257BQ34571474-E154C6C9-ADEA-4DE5-B87A-EA2D04790CB5Q35599319-0E145DFA-41A0-4B02-AB33-B21A0DF3FBF4Q37101977-C83AB8E7-3E73-417F-A312-64B172F4D4BFQ37316842-86F0A942-C7A4-4ECC-B7B4-DA58AC9D3F7DQ45857526-A80E5D33-23E6-4575-978E-69416FABC0B0Q45871873-3B204EB3-09FD-466B-9D88-DC0C302CD7FEQ47767564-00A1DA81-4D1E-4900-AA04-C68ACB4432E2
P2860
Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Increased therapeutic efficacy ...... of the full-length E3 region.
@en
type
label
Increased therapeutic efficacy ...... of the full-length E3 region.
@en
prefLabel
Increased therapeutic efficacy ...... of the full-length E3 region.
@en
P2093
P2860
P356
P1433
P1476
Increased therapeutic efficacy ...... of the full-length E3 region.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.CGT.7701117
P50
P577
2008-01-11T00:00:00Z
P6179
1003538677